{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:28:03Z","timestamp":1789450083542,"version":"build-2803163510"},"reference-count":25,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            An experimental bivalent meningococcal outer membrane vesicle (OMV) vaccine (B:4:P1.19,15 and B:4:P1.7-2,4) has been developed to provide wide vaccine coverage particularly of the circulating strains in Europe. A randomized, controlled phase II study (study identification number, 710158\/002; ClinicalTrials.gov identifier number, NCT00137917) to evaluate the immunogenicity and safety of three doses of the OMV vaccine when given to healthy 12- to 18-year-olds on a 0-2-4 month (\n            <jats:italic>n<\/jats:italic>\n            = 162) or 0-1-6 month schedule (\n            <jats:italic>n<\/jats:italic>\n            = 159). A control group received two doses of hepatitis A and one of conjugated meningococcal serogroup C vaccine on a 0-1-6 month schedule (\n            <jats:italic>n<\/jats:italic>\n            = 157). Immune response, defined as a fourfold increase in serum bactericidal titer using a range of vaccine-homologous or PorA-related and heterologous strains, was determined for samples taken before and 1 month after vaccination; assays were performed at two laboratories. As measured at the GlaxoSmithKline (GSK) laboratory, the OMV vaccine induced an immune response against homologous or PorA-related strains (in at least 51% of subjects against strains of serosubtype P1.19,15 and at least 66% against strains of serosubtype P1.7-2,4) and against a set of three heterologous strains (in 28% to 46% of subjects). Both laboratories showed consistent results for immune response rates. The OMV vaccine had a similar reactogenicity profile for each schedule. Pain preventing normal activities occurred in approximately one-fifth of the subjects; this was significantly higher than in the control group. The immune responses induced by the bivalent OMV vaccine demonstrated the induction of bactericidal antibodies against the vaccine-homologous\/PorA-related strains but also against heterologous strains, indicating the presence of protective antigens in OMVs and confirming the potential of clinical cross-protection.\n          <\/jats:p>","DOI":"10.1128\/cvi.00230-06","type":"journal-article","created":{"date-parts":[[2007,1,4]],"date-time":"2007-01-04T23:42:55Z","timestamp":1167954175000},"page":"65-73","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":48,"title":["Immunogenicity and Safety of Three Doses of a Bivalent (B:4:P1.19,15 and B:4:P1.7-2,4) Meningococcal Outer Membrane Vesicle Vaccine in Healthy Adolescents"],"prefix":"10.1128","volume":"14","author":[{"given":"Dominique","family":"Boutriau","sequence":"first","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Meningococcal Reference Unit, Health Protection Agency, Manchester, United Kingdom"},{"name":"Centro de Salud Nazaret, Valencia, Spain"},{"name":"Vaccines Institute of Valencia, Valencia, Spain"},{"name":"Grupo de Investigacio\u0301n de Atencio\u0301n Primaria de Castello\u0301n, Centro de Salud Pu\u0301blica, Castello\u0301n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Poolman","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Meningococcal Reference Unit, Health Protection Agency, Manchester, United Kingdom"},{"name":"Centro de Salud Nazaret, Valencia, Spain"},{"name":"Vaccines Institute of Valencia, Valencia, Spain"},{"name":"Grupo de Investigacio\u0301n de Atencio\u0301n Primaria de Castello\u0301n, Centro de Salud Pu\u0301blica, Castello\u0301n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Meningococcal Reference Unit, Health Protection Agency, Manchester, United Kingdom"},{"name":"Centro de Salud Nazaret, Valencia, Spain"},{"name":"Vaccines Institute of Valencia, Valencia, Spain"},{"name":"Grupo de Investigacio\u0301n de Atencio\u0301n Primaria de Castello\u0301n, Centro de Salud Pu\u0301blica, Castello\u0301n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Findlow","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Meningococcal Reference Unit, Health Protection Agency, Manchester, United Kingdom"},{"name":"Centro de Salud Nazaret, Valencia, Spain"},{"name":"Vaccines Institute of Valencia, Valencia, Spain"},{"name":"Grupo de Investigacio\u0301n de Atencio\u0301n Primaria de Castello\u0301n, Centro de Salud Pu\u0301blica, Castello\u0301n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Diez","family":"Domingo","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Meningococcal Reference Unit, Health Protection Agency, Manchester, United Kingdom"},{"name":"Centro de Salud Nazaret, Valencia, Spain"},{"name":"Vaccines Institute of Valencia, Valencia, Spain"},{"name":"Grupo de Investigacio\u0301n de Atencio\u0301n Primaria de Castello\u0301n, Centro de Salud Pu\u0301blica, Castello\u0301n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Puig-Barbera","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Meningococcal Reference Unit, Health Protection Agency, Manchester, United Kingdom"},{"name":"Centro de Salud Nazaret, Valencia, Spain"},{"name":"Vaccines Institute of Valencia, Valencia, Spain"},{"name":"Grupo de Investigacio\u0301n de Atencio\u0301n Primaria de Castello\u0301n, Centro de Salud Pu\u0301blica, Castello\u0301n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose\u0301 Mari\u0301a","family":"Baldo\u0301","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Meningococcal Reference Unit, Health Protection Agency, Manchester, United Kingdom"},{"name":"Centro de Salud Nazaret, Valencia, Spain"},{"name":"Vaccines Institute of Valencia, Valencia, Spain"},{"name":"Grupo de Investigacio\u0301n de Atencio\u0301n Primaria de Castello\u0301n, Centro de Salud Pu\u0301blica, Castello\u0301n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Planelles","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Meningococcal Reference Unit, Health Protection Agency, Manchester, United Kingdom"},{"name":"Centro de Salud Nazaret, Valencia, Spain"},{"name":"Vaccines Institute of Valencia, Valencia, Spain"},{"name":"Grupo de Investigacio\u0301n de Atencio\u0301n Primaria de Castello\u0301n, Centro de Salud Pu\u0301blica, Castello\u0301n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angels","family":"Jubert","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Meningococcal Reference Unit, Health Protection Agency, Manchester, United Kingdom"},{"name":"Centro de Salud Nazaret, Valencia, Spain"},{"name":"Vaccines Institute of Valencia, Valencia, Spain"},{"name":"Grupo de Investigacio\u0301n de Atencio\u0301n Primaria de Castello\u0301n, Centro de Salud Pu\u0301blica, Castello\u0301n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Colomer","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Meningococcal Reference Unit, Health Protection Agency, Manchester, United Kingdom"},{"name":"Centro de Salud Nazaret, Valencia, Spain"},{"name":"Vaccines Institute of Valencia, Valencia, Spain"},{"name":"Grupo de Investigacio\u0301n de Atencio\u0301n Primaria de Castello\u0301n, Centro de Salud Pu\u0301blica, Castello\u0301n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Gil","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Meningococcal Reference Unit, Health Protection Agency, Manchester, United Kingdom"},{"name":"Centro de Salud Nazaret, Valencia, Spain"},{"name":"Vaccines Institute of Valencia, Valencia, Spain"},{"name":"Grupo de Investigacio\u0301n de Atencio\u0301n Primaria de Castello\u0301n, Centro de Salud Pu\u0301blica, Castello\u0301n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Levie","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Meningococcal Reference Unit, Health Protection Agency, Manchester, United Kingdom"},{"name":"Centro de Salud Nazaret, Valencia, Spain"},{"name":"Vaccines Institute of Valencia, Valencia, Spain"},{"name":"Grupo de Investigacio\u0301n de Atencio\u0301n Primaria de Castello\u0301n, Centro de Salud Pu\u0301blica, Castello\u0301n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Diane","family":"Kervyn","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Meningococcal Reference Unit, Health Protection Agency, Manchester, United Kingdom"},{"name":"Centro de Salud Nazaret, Valencia, Spain"},{"name":"Vaccines Institute of Valencia, Valencia, Spain"},{"name":"Grupo de Investigacio\u0301n de Atencio\u0301n Primaria de Castello\u0301n, Centro de Salud Pu\u0301blica, Castello\u0301n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Weynants","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Meningococcal Reference Unit, Health Protection Agency, Manchester, United Kingdom"},{"name":"Centro de Salud Nazaret, Valencia, Spain"},{"name":"Vaccines Institute of Valencia, Valencia, Spain"},{"name":"Grupo de Investigacio\u0301n de Atencio\u0301n Primaria de Castello\u0301n, Centro de Salud Pu\u0301blica, Castello\u0301n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Dominguez","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Meningococcal Reference Unit, Health Protection Agency, Manchester, United Kingdom"},{"name":"Centro de Salud Nazaret, Valencia, Spain"},{"name":"Vaccines Institute of Valencia, Valencia, Spain"},{"name":"Grupo de Investigacio\u0301n de Atencio\u0301n Primaria de Castello\u0301n, Centro de Salud Pu\u0301blica, Castello\u0301n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Barbera\u0301","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Meningococcal Reference Unit, Health Protection Agency, Manchester, United Kingdom"},{"name":"Centro de Salud Nazaret, Valencia, Spain"},{"name":"Vaccines Institute of Valencia, Valencia, Spain"},{"name":"Grupo de Investigacio\u0301n de Atencio\u0301n Primaria de Castello\u0301n, Centro de Salud Pu\u0301blica, Castello\u0301n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin","family":"Sotolongo","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Meningococcal Reference Unit, Health Protection Agency, Manchester, United Kingdom"},{"name":"Centro de Salud Nazaret, Valencia, Spain"},{"name":"Vaccines Institute of Valencia, Valencia, Spain"},{"name":"Grupo de Investigacio\u0301n de Atencio\u0301n Primaria de Castello\u0301n, Centro de Salud Pu\u0301blica, Castello\u0301n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Aase A. T. K. Herstad L. M. Naess T. E. Michaelsen and D. R. Martin. 2004. Opsonophagocytic activity of human sera after vaccination with two different group B meningococcal vaccines in a clinical trial in New Zealand abstr. 63. Abstracts of the 14th International Pathogenic Neisseria Conference Milwaukee Wis."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","volume":"338","year":"1991","unstructured":"Bjune, G., E. A. Holby, J. K. Gronnesby, O. Arnesen, J. H. Fredriksen, A. Halstensen, E. Holten, A. K. Lindbak, H. Nokleby, and E. Rosenqvist. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338:1093-1096.","journal-title":"Lancet"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/CDLI.12.8.970-976.2005","volume":"12","year":"2005","unstructured":"Borrow, R., I. S. Aaberge, G. F. Santos, T. L. Eudey, P. Oster, A. Glennie, J. Findlow, E. A. H\u00f8iby, E. Rosenqvist, P. Balmer, and Martin. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity using human complement against meningococcal serogroup B, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol.12:970-976.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0264-410X(01)00254-7","volume":"20","year":"2001","unstructured":"Bos, J. M., H. C. R\u00fcmke, R. Welte, M. J. Postma, and J. C. Jager. 2001. Heath economics of an hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination programme. Vaccine20:202-207.","journal-title":"Vaccine"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","volume":"13","year":"1995","unstructured":"Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martinez, J. Arthur, P. Underwood, and W. Silva. 1995. Efficacy, safety and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine13:821-829.","journal-title":"Vaccine"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0264-410X(00)00320-0","volume":"19","year":"2000","unstructured":"de Kleijn, E. D., R. de Groot, A. B. Lafeber, J. Labadie, K. C. J. P. van Limpt, J. Visser, G. A. M. Berbers, L. van Alphen, and H. C. R\u00fcmke. 2000. Immunogenicity and safety of monovalent P1.7h,4 meningococcal outer membrane vesicle vaccine in toddlers: comparison of two vaccination schedules and two formulations. Vaccine19:1141-1148.","journal-title":"Vaccine"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","volume":"340","year":"1992","unstructured":"de Moraes, J. C., B. A. Perkins, M. C. C. Camargo, N. T. Hidalgo, H. A. Barbosa, C. T. Sacchi, I. M. Landgraf, V. L. Gattas, and H. G. Vasconcelos. 1992. Protective efficacy of a serogroup B meningococcal vaccine in S\u00e3o Paulo, Brazil. Lancet340:1074-1078.","journal-title":"Lancet"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","year":"1969","unstructured":"Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of natural humoral antibodies. J. Exp. Med.129:1307-1326.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","volume":"21","year":"2003","unstructured":"Holst, J., B. Feiring, J. E. Fuglesang, E. A. Hoiby, H. Nokleby, I. S. Aaberge, and E. Rosenqvist. 2003. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccine against Neisseria meningitidis serogroup B disease. Vaccine21:734-737.","journal-title":"Vaccine"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(02)08416-7","volume":"359","year":"2002","unstructured":"J\u00f3dar, L., I. M. Feavers, D. Salisbury, and D. M. Granoff. 2002. Development of vaccines against meningococcal disease. Lancet359:1499-1508.","journal-title":"Lancet"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.vaccine.2005.01.070","volume":"23","year":"2005","unstructured":"Martin, D. R., L. McCallum, A. Gennie, N. Ruijne, P. Blatchford, J. O'Hallahan, and P. Oster. 2005. Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials. Vaccine23:2218-2221.","journal-title":"Vaccine"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.10.4419-4424.1994"},{"key":"e_1_3_2_14_2","unstructured":"Surveillance of bacterial meningitis in Europe 1999\/2000 2002"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/ije\/24.5.1050","volume":"24","year":"1995","unstructured":"Noronha, C. P., C. J. Struchiner, and M. E. Halloran. 1995. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int. J. Epidemiol.24:1050-1057.","journal-title":"Int. J. Epidemiol."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","volume":"23","year":"2005","unstructured":"Oster, P., D. Lennon, J. O'Hallahan, K. Mulholland, S. Reid, and D. Martin. 2005. MeNZB\u2122: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine23:2191-2196.","journal-title":"Vaccine"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1086\/514232","volume":"177","year":"1998","unstructured":"Perkins, B. A., K. Jonsdottir, H. Briem, E. Griffiths, B. D. Plikaytis, E. A. Hoiby, E. Rosenqvist, J. Holst, H. Nokleby, F. Sotolongo, G. Sierra, H. C. Campa, G. M. Carlone, D. Williams, J. Dykes, D. Kapczynski, E. Tikhomirov, J. D. Wenger, and C. V. Broome. 1998. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis.177:683-691.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_18_2","first-page":"323","volume":"92","year":"1998","unstructured":"Rosenqvist, E., E. A. Hoiby, G. Bjune, A. Aase, A. Halstensen, A. Lehmann, J. Paulssen, J. Holst, T. Michaelsen, H. Nokleby, L. Froholm, and O. Closs. 1998. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine. Dev. Biol. Stand.92:323-333.","journal-title":"Dev. Biol. Stand."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.12.4642-4652.1995"},{"key":"e_1_3_2_20_2","first-page":"195","volume":"14","year":"1991","unstructured":"Sierra, G. V. G., H. C. Campa, N. M. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez, and M. H. Terry. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Annals14:195-210.","journal-title":"NIPH Annals"},{"key":"e_1_3_2_21_2","first-page":"1520","volume":"281","year":"1999","unstructured":"Tappero, J. W., R. Lagos A. M. Ballesteros, B. Plikaytis, D. Williams, J. Dykes, L. L. Gheesling, G. M. Carlone, E. A. Hoiby, J. Holst, H. Nokleby, E. Rosenqvist, G. Sierra, C. Campa, F. Sotolongo, J. Vega, J. Garcia, P. Herrera, J. T. Poolman, and B. A. Perkins. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines. A randomized controlled trial in Chile. JAMA281:1520-1527.","journal-title":"JAMA"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.8.4694-4703.2005"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.4.1650-1655.2003"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1086\/379375","volume":"188","year":"2003","unstructured":"Welsch, J. A., G. R. Moe, R. Rossi, et al. 2003. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J. Infect. Dis.188:1730-1740.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.4049\/jimmunol.172.9.5606","volume":"172","year":"2004","unstructured":"Welsch, J. A., R. Rossi, M. Comanducci, and D. M. Granoff. 2004. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J. Immunol.172:5606-5615.","journal-title":"J. Immunol."},{"key":"e_1_3_2_26_2","first-page":"183","volume":"1981","year":"1981","unstructured":"World Health Organization. 1981. Thirty-first report of the WHO Expert Committee on Biological Standardization: WHO technical report series, no. 658. Annex 5. Amendment. WHO Tech. Rep. Ser.1981:183-184.","journal-title":"WHO Tech. Rep. Ser."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00230-06","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00230-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:37:31Z","timestamp":1627591051000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00230-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1128\/CVI.00230-06"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00230-06","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]},"assertion":[{"value":"2006-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-10-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}